Abbott Labs reported earnings this morning that were slightly better than expected and raised guidance slightly for next year (via Reuters):

Abbott Laboratories Inc, which spun off its branded prescription drugs business earlier this month, on Wednesday forecast 2013 earnings above Wall Street expectations.

Abbott said it expects earnings for the full year, excluding special items, of $1.98 to $2.04 per share. Analysts, on average, have forecast $1.95, according to Thomson Reuters I/B/E/S.

Abbott is part of our Global Opportunities portfolio. We’ll update this post after reviewing the quarter.

For information on Alhambra Investment Partners’ money management services and global portfolio approach to capital preservation, Joe Calhoun can be reached at: jyc3@4kb.d43.myftpupload.com or    786-249-3773.

Click here to sign up for our free weekly e-newsletter.